

Heart Failure Society of America Review

Economic Issues in Heart Failure in the United States

PAUL A. HEIDENREICH, MD, MS,^{1,2} GREGG C. FONAROW, MD,³ YEKATERINA OPSHA, PharmD BCPS-AQ Cardiology,^{4,5}
ALEXANDER T. SANDHU, MD,¹ NANCY K. SWEITZER, MD, PhD,⁶ AND HAIDER J. WARRAICH, MD^{7,8},

Stanford, Palo Alto, and Los Angeles, California; Piscataway, and Livingston, New Jersey; Tucson, Arizona; and Boston, Massachusetts

HFSA Scientific Statement Committee Members Chair

Javed Butler, MD, *Chair*

Eileen Hsich, MD
Susan Bennett Pressler, PhD, RN
Kevin Shah, MD

Kenneth Taylor, MD
Marwa Sabe, MD, MPH
Tien Ng, PharmD

LAY SUMMARY

The cost of heart failure care is high owing to the cost of hospitalization and chronic treatments. Heart failure treatments vary in their benefit and cost. The cost effectiveness of therapies can be determined by comparing the cost of treatment required to obtain a certain benefit, often defined as an increase in 1 year of life. This review was sponsored by the Heart Failure Society of America and describes the growing economic burden of heart failure for patients and the health care system in the United States. It also provides a summary of the cost effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure. Many medications that are no longer under patent are inexpensive and highly cost-effective. These include angiotensin-converting enzyme inhibitors, beta-blockers and mineralocorticoid receptor antagonists. In contrast, more recently developed medications and devices, vary in cost effectiveness, and often have high out-of-pocket costs for patients. (*J Cardiac Fail* 2022;28:453–466)

Despite remarkable recent advances in the treatment of heart failure, the high cost of care limits delivery of effective care. The Heart Failure Society of America (HFSA) recognizes the important role of cost, cost effectiveness, and value of diagnosis and treatment in caring for patients with heart failure. This review sponsored by HFSA describes the economic burden of heart failure, providing a summary of evidence for the cost effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure.

Formation of the Writing Group

The Advocacy Committee of the HFSA requested its members consider developing a manuscript on

economic issues in heart failure. This effort was led by the incoming committee Chair (P.A.H.) and included committee members and noncommittee members of the HFSA with expertise in this area.

Economic Burden of Heart Failure

Heart failure is a growing burden for the United States and other developed countries due in large part to the aging of their populations. The incidence is approximately 1,000,000 new patients with heart failure per year in the United States.¹ Accordingly, the cost of care for patients with heart failure is substantial. By 2030 it is estimated that more than 8 million individuals in the United States will have heart failure for a prevalence rate of 1 in every 33 individuals.² The

From the ¹Department of Medicine, Stanford University School of Medicine, Stanford, California; ²VA Palo Alto Health Care System, Palo Alto, California; ³Division of Cardiology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California; ⁴Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey; ⁵Saint Barnabas Medical Center, Livingston, New Jersey; ⁶Division of Cardiology, University of Arizona College of Medicine, Tucson, Arizona; ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts and ⁸Department of Medicine, Cardiology Section, VA Boston Healthcare System, Boston, Massachusetts.

Manuscript received July 13, 2021; revised manuscript received November 16, 2021; revised manuscript accepted December 20, 2021.

Reprint requests: Paul Heidenreich MD, MS, 111 Medicine, 3801 Miranda Ave, Palo Alto, CA 94304; Tel: 650-849-1205; Fax 650-852-3473.

E-mail: heiden@stanford.edu

See page 462 for disclosure information.

1071-9164/\$ - see front matter

© 2022 Published by Elsevier Inc.

<https://doi.org/10.1016/j.cardfail.2021.12.017>

annual cost of caring for a patient with heart failure is near \$30,000 in the United States, with a wide range of estimates for other countries.^{3–6} The majority of this cost is accrued for inpatient care (Fig. 1).

The economic impact of heart failure is best estimated by the incremental cost owing to heart failure and not the entire cost of care. The incremental cost includes both direct treatment of heart failure, as well as the increase in cost owing to heart failure worsening other conditions. In 2012, the American Heart Association estimated the cost attributable to heart failure care to be \$3600 in direct cost and \$1700 in indirect costs per patient per year.² Indirect costs include cost of lost employment and are typically included in societal cost analyses. By 2030, US heart failure costs are expected to be at least \$70 billion per year (\$244 per every US adult) with total cost of caring for patients with heart failure reaching \$160 billion.² Data from Canada show similar trends with an estimated cost of \$722 million by 2030 for a principal diagnosis of heart failure and \$2.8 billion when secondary diagnoses are included.³

Hospitalization Trends

The greatest economic burden related to heart failure results from hospitalizations and rehospitalizations. In many analyses, 75%–80% of the direct costs for heart failure are attributable to inpatient hospital stays.^{1,2} In 2016, there were 809,000 hospital discharges with a primary diagnosis of heart failure and another 2–3 million hospitalizations with heart failure as a secondary diagnosis.¹ Heart failure primarily affects older adults, is the second most common inpatient diagnosis billed to Medicare, and has among one of the highest 30-day readmission rates of any other medical or surgical condition.^{1,2,7} Patients with heart failure requiring inpatient admission are a highly vulnerable population and have a poor prognosis, with 1-year mortality rates exceeding 30%.^{1,2,7}

From 2005 to 2014, hospitalizations for heart failure in the United States increased, largely driven by increased admissions for heart failure with preserved left ventricular ejection fraction.⁸ However, after 2014, hospitalizations for heart failure per capita decreased in the United States.¹ The reasons for this decrease are unclear and likely multifactorial. Per the National Inpatient Sample, heart failure hospitalizations in the United States decreased from 1,000,000 per year in 2002 to 800,000 per year in 2016.⁴ The mean hospital length of stay also decreased by 2 days from 8.6 to 6.5 days during this time. Despite the decrease in length of stay, the cost per hospitalization (in constant dollars) has increased 1.4% per year to \$19,000 in 2016 dollars.

This increase in cost per hospitalization was associated with more procedures and a greater prevalence

of cardiogenic shock and renal failure requiring dialysis.⁴ The decrease in the length of stay was associated with fewer discharges to home (70%–65%) and more discharges to long-term care facilities.⁴ The reasons for a decrease in hospitalizations is likely multifactorial. Although improvements in the provision of guideline-recommended care is a possible contributor, increased attention to readmission may have prompted providers to attempt outpatient management strategies for patients who would have been previously been hospitalized, although it is not clear that financial penalties had a direct effect.⁸

Readmissions

The worldwide prevalence of heart failure is estimated to be 26 million and is increasing.¹ In the United States, 5.7 million adults have been diagnosed with heart failure, with estimated annual direct costs of \$39.2 billion to \$60 billion.^{2,3} Total heart failure costs in the United States are expected to exceed \$70 billion by 2030⁴

Heart failure primarily affects older persons and is the second most common inpatient diagnosis billed to Medicare.⁵ Patients with heart failure requiring inpatient admission are a vulnerable population and have a poor long-term prognosis, with a 2-year readmission-free survival rate as low as 17%.⁶ The risks of death and rehospitalization are accentuated immediately after inpatient discharge, with much of the economic burden in heart failure resulting from costly hospital readmissions. Several groups have identified transition-of-care interventions after acute hospitalization as an important area to improve patient safety and reduce heart failure costs.^{4,7}

Several groups have identified targeting reductions in readmissions after a heart failure hospitalization as an important area to reduce heart failure costs. In 2007, the Medicare Payment Advisory Commission estimated that a substantial portion of Medicare beneficiaries experience a preventable hospital readmission within 30 days of discharge and recommended focusing on decreasing readmissions.⁹ Under the 2010 Patient Protection and Affordable Care Act, the mandatory federal Hospital Readmissions Reduction Program (HRRP) was created to decrease 30-day hospital readmissions. Readmissions reporting started in 2010 and the financial penalty phase began in 2012, with hospitals with higher than expected 30-day all-cause Medicare fee-for-service readmissions after an initial hospitalization for heart failure, acute myocardial infarction, and pneumonia, penalized up to 3% of their total inpatient Medicare payments.⁹ In fiscal year 2020, 83% of Medicare-participating hospitals were penalized, for a total of \$563 million dollars.⁹ The HRRP has altered the landscape of hospital readmissions

and reimbursement within the United States, with \$7.7 billion in otherwise owed reimbursement to hospitals budgeted to be withheld in the first 10 years of the program.⁹ Because hospitals that care for patients with heart failure with lower socioeconomic status tend to have higher readmission rates, irrespective of care quality, safety net and other financially vulnerable hospitals have been disproportionately impacted by these penalties.⁹ Although the HRRP was associated with decreases in inpatient 30-day rehospitalization rates for patients with heart failure, much of the observable changes in practices after HRRP seem to have resulted from administrative upcoding and inappropriate triage, rather than improvements in transitions of care, outpatient disease management, and use of evidence-based, guideline-directed clinical practices.⁹ When adjusted for coding changes, observed decreases were comparable with hospitals not subject to financial penalties for readmissions, suggesting either no effect or an effect independent of the penalty.⁹ Of greater concern, some studies,^{10,11} although not all¹² have suggested that, after the HRRP announcement and penalty phase, patients hospitalized with heart failure have had increases in postdischarge mortality.

Transitions of Care

Although the financial penalty-based policy approach seems to have been associated with unintended consequences, a number of care transition and heart failure disease management interventions have shown some success in decreasing readmissions without compromising patient safety.^{1,13,14} The interventions used by these programs include initiating discharge planning early in the course of hospital care, collaborating with pharmacy services in discharge planning, actively involving patients and families or caregivers in the plan of care, providing new processes and systems that ensure patient understanding of education about the plan of care before discharge from the hospital, and improving quality of care by continually monitoring adherence to national evidence-based guidelines.¹⁴ A formal economic analysis of transitional care services after a hospitalization for heart failure, including disease management, nurse home visits and nurse case management, have suggested these are cost-effective strategies.¹³ Although many care coordination and transitions programs were found to decrease readmissions and costs of heart failure care, not all programs have been shown to be effective.¹⁵




Fig. 1. The breakdown of cost of care is shown for care types (2010 resource use).⁵ Because this study was performed, it is likely that care has shifted slightly to the outpatient setting.

Outpatient Trends

In contrast with the recent decline in hospitalizations, outpatient care for heart failure has increased.¹ In 2016, there were 1,932,000 office visits and 414,000 emergency department visits with a primary diagnosis of heart failure.¹ As more ambulatory care systems accept capitation or other increased risk of patient cost there will be more pressure to decrease hospitalizations and emergency department visits.

Disparities

Racial disparities in heart failure hospitalizations have been demonstrated with higher age-adjusted rates among Black patients compared with other races.¹⁶ Data from the Atherosclerosis Risk in Communities (ARIC) study from 2005 to 2014 demonstrated a higher age-adjusted rate of heart failure hospitalization for Black men (38.1 [36.6–39.7]) per 1000 per year) than for White men (20.7 [20.0–21.3]) per 1000 per year).¹⁶ Similar differences were noted for Black women (30.5 [29.2–31.8]) compared with White women (15.2 [14.7–15.7]). Furthermore, the trends over time indicate that rates were increasing at a faster rate over 10 years for Black men (+3.7%) and Black women (+4.3%) than for White men (+2.6%) and White women (+1.9%).¹⁶

Impact of the COVID-19 Pandemic on Heart Failure Cost of Care

During the initial phase of the COVID-19 pandemic (through the summer of 2020) the rate of heart failure hospitalizations decreased by 30%–40% in many countries.^{17–20} A similar decrease in emergency department visits (44%)¹⁸ was observed. The reasons for this are unclear and may be due in part to patient concerns about seeking care and hospitals being overwhelmed caring for COVID-19 patients. Further surveillance will be needed to assess whether this decline in hospitalizations is associated with an increase in mortality or will lead to a rebound in hospitalizations over time.²¹

The COVID-19 pandemic has also accelerated the use of virtual visits²² to decrease the transmission of COVID-19. These virtual visits do not incur facility or patient transportation costs, although patients are often still subject to copays. It is likely that the use of such visits will persist when COVID-19 is no longer a significant public health threat. Yet, it is unclear whether the quality of heart failure care provided, and clinical outcomes produced are comparable to those of in-person visits. Currently, compensation for video visits remains comparable with in-person visits in the United States, although it is not clear how long this will last. Telemedicine has also been

used for the delivery of cardiac rehabilitation for patients for heart failure and this method is likely to continue.²³ Thus, the cost of outpatient heart failure care may have decreased during the COVID-19 pandemic, with the potential impact on overall quality, costs, and outcomes requiring further study.

Measuring the Economic Value of Heart Failure Care

Value of care is often measured in units of cost per life-year gained with lower ratios indicating higher value (incremental cost-effectiveness ratio). The American College of Cardiology and the American Heart Association have adopted the World Health Organization recommendation of adjusting the threshold for value using the wealth of society as measured by the gross domestic product (GDP).²⁴ Specifically, a treatment is considered high value if the cost per life year (or quality-adjusted life-year) gained is less than 1 GDP per capita.²⁴ The GDP/capita in the United States in 2019 was approximately \$65,000.²⁵ If the cost per quality-adjusted life-year gained is more than 3 GDP/capita, then the value is considered poor. A similar threshold for poor value was identified using an opportunity cost approach that estimated how much individuals are willing to pay for health by comparing the amount individuals were willing to pay for private insurance against the clinical harms of not having insurance.²⁶ The uncertainty in the estimated cost-effectiveness varies and should be considered when evaluating the value of care. Fig. 2 shows an estimate both the cost-effectiveness ratio and the uncertainty in the estimate for different heart failure care strategies.

Medications

Cost-Effectiveness of Current Heart Failure Therapies

Multiple pharmacologic therapies improve survival among patients with heart failure with reduced ejection fraction^{14,27}: selected beta-blockers, angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers, mineralocorticoid receptor antagonists, hydralazine/nitrate, sacubitril-valsartan, and sodium glucose cotransporter-2 inhibitors.^{14,27} Ivabradine is an additional therapy that has been shown to improve quality of life and decrease heart failure hospitalizations.²⁷ Cost-effectiveness studies have evaluated the economic value of these heart failure drugs.^{28–41} These studies, described in Table 1, have consistently demonstrated the high value of these therapies at conventional US cost-effectiveness thresholds.^{24,26}

Most economic analyses were performed soon after the pivotal clinical trials and therapy introduction. Owing to the timing of these analyses, there

are important considerations that affect their enduring applicability. First, heart failure therapies have been additive with each treatment added to prior therapies, resulting in a decrease in heart failure mortality over time.¹ The economic analyses of earlier agents, such as beta-blocker or ACE-I therapy, were based on trials with a higher baseline mortality and subsequently greater absolute clinical benefit than observed currently. The nonpharmaceutical costs of treating heart failure have increased over time.⁴² Critically important is the decrease in a drug's price after generic availability, particularly for beta-blockers, ACE-Is, and angiotensin receptor blockers. A more recent economic analysis demonstrated high value at generic prices.³⁸

Three major heart failure drug classes remain under patent in 2021: sacubitril-valsartan, ivabradine, and sodium glucose cotransporter-2 inhibitors. Multiple studies have demonstrated the high value of sacubitril-valsartan.^{31,36,43} Additionally, a recent analysis based on PIONEER-HF demonstrated sacubitril-valsartan was potentially cost saving among high-risk patients hospitalized for heart failure when indirect societal costs (costs owing to lost employment) were taken into account.⁴⁴ Ivabradine has one industry-sponsored cost-effectiveness study that also demonstrated high value.³³ Several sodium glucose cotransporter-2 inhibitors are approved by the US Food and Drug Administration for the treatment of heart failure among patients with and without diabetes. There is a

published cost-effectiveness evaluation demonstrating intermediate value with dapagliflozin using US prices.⁴⁵ Rapid analyses of the economic value of new therapies are critical to inform payer–manufacturer price negotiations and health care system supply for novel therapies. Likewise, there must continue to be updated analyses in the setting of changing prices and changes in heart failure epidemiology and costs.

Additional heart failure-related therapies are worth discussion. Tafamadis is an approved therapy for cardiomyopathy owing to transthyretin amyloidosis that improves survival and quality of life.⁴⁶ At its current wholesale acquisition cost of \$225,000 annually, it has an incremental cost-effectiveness ratio of \$880,000/quality-adjusted life-years, which would be low value based on conventional US thresholds.⁴⁷ Although wholesale acquisition costs are typically the best estimate of the cost of drug therapy, the company may provide discounts that decrease the overall cost of care. Cost-effectiveness analyses typically examine a range of drug costs that will include the cost after any discount. Patiromer acetate, a potassium binding agent, is used to enable use of ACE-I, angiotensin receptor blocker, and mineralocorticoid receptor antagonist therapy among patients with hyperkalemia. A single, industry-sponsored analysis found patiromer had an incremental cost-effectiveness ratio of \$52,700 per quality-adjusted life-year.⁴⁸ This study made strong assumptions regarding the overall clinical impact of




Fig. 2. Graphical representation of studies cost-effectiveness for different heart failure therapies. Value estimates are measured on the x axis in terms of cost per quality-adjusted life-years gained. The y axis shows the uncertainty in these estimates. The box outlining MRA, ACE/ARB, and beta-blockers indicates similar value estimates and certainty of value for these groups. ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist; ARNI, angiotensin receptor blocker and neprilysin inhibitor; BNP, B-type natriuretic peptide; CRT, cardiac resynchronization therapy; D/C, discharge; GDP, gross domestic product; ICD, implantable cardioverter defibrillator; LVAD, left ventricular assist device; MRA, mineralocorticoid receptor antagonists; QALY, quality-adjusted life-years; SGLT-2, sodium glucose co-transporter-2 inhibitors.

patiromer based on the OPAL-HK trial, a single-arm study of patients with hyperkalemia and chronic kidney disease (including patients without heart failure) that demonstrated patiromer's potassium-lowering effect.⁴⁹ With limited effectiveness data, the economic value of patiromer remains uncertain.

Budget Impact of New Therapies to the System

Health care payers may be more concerned with a therapy's impact on its short-term total budget than on its long-term cost effectiveness. The focus on budgetary impact is a product of multiple realities of the health care system. First, patients change insurances frequently. Therefore, an insurance company may be more affected by short-term costs than long-term effects. Second, insurance companies must balance their short-term budget. An increase in spending related to a given drug must be offset with other budget adjustments until premiums are adjusted. Finally, US payers do not have accepted cost-effectiveness thresholds at which therapies are considered reasonable value for coverage. Therefore, effective therapies are approved, but barriers are erected, such as preauthorization requirements, to limit uptake and minimize the budgetary impact.

There are limited data regarding the budgetary impact of new therapies. The Institute for Clinical and Economic Review estimated the cost-effectiveness and budgetary impact of sacubitril-valsartan soon after its approval. It found a similar cost effectiveness to other analyses.^{50,51} Based on a high uptake of sacubitril-valsartan (75% of patients by year 5) given the substantial therapeutic benefit, it estimated a \$3.0 billion annual budgetary impact. The report also calculated a value-based price benchmark. This price assumes a drug's budgetary impact should be proportional to other drugs irrespective of its relative value (\$900 million per drug) or disease prevalence. Based on this analysis, sacubitril-valsartan's estimated price should be at least 9% below the wholesale acquisition cost.

Focusing on budgetary impacts biases against therapies for high-prevalence conditions. New heart failure therapies will have high budgetary impact owing to heart failure's prevalence. Limiting the total spending on a drug independent of its value or disease prevalence ignores the potential to improve clinical outcomes for more patients. Coverage and pricing decisions should focus on the value of therapy rather than on the budgetary impact.

Barriers to Access

Multiple barriers have prevented optimal uptake of heart failure drugs. These include barriers erected by insurance companies—prior authorizations, copays, and deductibles—that are intended to

reduce inappropriate use, in part by forcing patients to share the cost. Unfortunately, these processes also block the adoption of high-value therapies and decrease appropriate use.⁵²

Conceptually, prior authorization requirements restrict high-cost treatment to scenarios with evidence of clinical benefit.⁵³ However, the process also exacerbates the challenge of prescribing novel therapies to patients who will benefit. Prior authorization requirements are often applied indiscriminately across high-cost drugs, independent of a patient's clinical characteristics. Even for those patients most likely to benefit from a therapy, gaining authorization is a time-intensive process that increases the barriers to prescribing high-value therapies. For most heart failure drugs, there is little evidence of inappropriate use or indication drift, so prior authorization has minimal benefit with the potential for significant harm. Prior authorization requests for heart failure drugs should be limited to scenarios where a high-cost therapy is being used for an indication with unclear benefit or where there are clinically equivalent substitutes with lower costs.

The unaffordability of heart failure therapies is a second major barrier to access. Patients are required to pay high out-of-pocket costs via copays and deductibles for many of the new cost-effective heart failure drugs. With guideline-directed heart failure management consisting of multiple therapies in addition to nonheart failure drugs, high total out-of-pocket costs can limit the affordability of heart failure treatment. Multiple studies have found high out-of-pocket costs are associated with lower rates of initial filled prescriptions and adherence to therapy.^{54,55} Additionally, randomized trials have demonstrated copay waivers can improve therapy adherence.^{56,57}

Drug cost sharing has 2 potential roles. First, it is an additional tool to decrease the overuse of therapies with minimal clinical benefit. Second, cost sharing may be used for effective therapies that are low value owing to high costs, although, even in this case, cost sharing would be expected to increase health disparities given that low-income patients are less likely to be able to afford the effective therapy.

For high-value drugs, placing the burden of payment on patients may inappropriately decrease therapy rates and worsen clinical outcomes. Sacubitril-valsartan is an example of a cost-effective drug that is unaffordable for many patients with heart failure, contributing to inadequate sacubitril-valsartan use and adherence, increasing heart failure morbidity and mortality.⁵⁸ Copays and deductibles should be minimal for high-value therapies like sacubitril-valsartan with current out-of-pocket costs covered by the insurance plan.⁵⁹ Prioritizing the affordability of high-value drugs is critical to

Table 1. Selected Cost-effectiveness Studies for Heart Failure Drugs*

Drug (Estimated 2018 Cost) [†]	First Author (Year)	Industry Sponsor	CEA Cost	LY; QALY Gain	Cost Difference	ICER (\$/QALY or \$/LY) [‡]	Comments
Beta-blockers							
Bisoprolol (\$188)	Gregory (2001) ³⁴	N	\$379	1.04; NA	\$3455	\$3336/ LY	Based on CIBIS-II trial; no QALY data
Carvedilol (\$55)	Delea (1999) ³⁷	Y	\$1096	0.79; NA	\$15,735	\$19,918/ LY	Based on US Carvedilol Trial; no QALY data
	Gregory (2001) ³⁴	N	\$2000	2.40; NA	\$15,656	\$6740/ LY	Based on US Carvedilol Trial; no QALY data
Metoprolol succinate (\$183)	Gregory (2001) ³⁴	N	\$612	1.06; NA	\$2613	\$2472/LY	Based on MERIT-HF and MDC Trial; no QALY data
Any (\$55) [§]	Banka (2013) ³⁸	N	\$48	0.31; 0.24	\$411	\$1323/ QALY	Based on MERIT-CHF trial
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers							
Captopril (\$812)	Tsevat (1995) ²⁹	Y	\$631	NA; 0.52	\$2933	\$5600/ QALY	Based on SAVE trial; results displayed for 60yo cohort
Enalapril (\$192)	Paul (1994) ³²	N	\$959	NA; 0.27	\$2569	\$9731/ LY	Based on SOLVD and V-HeFT-II trials; only a 10-year time horizon; no QALY data
	Glick (1995) ³⁵	Y	\$248	0.30; 0.21	\$25	\$115/ QALY	Based on SOLVD trial
Any (\$40) [§]	Banka (2013) ³⁸	N	\$48	0.15; 0.12	-\$444	Dominant Strategy [¶]	Based on SOLVD trial
	Shekelle (2003) ³⁰	N	\$520	0.64; 0.66	\$3718	\$5644/ QALY	Based on SOLVD trial
Mineralocorticoid receptor antagonists							
Eplerenone (\$961)	Weintraub (2005) ²⁸	Y	\$1138 [§]	0.06–0.13; 0.04–0.09	\$1923–\$2323		

\$23,724–\$43,301 Based on EPHEBUS trial** Any (\$78)[§]Banka (2013)³⁸\$480.10; 0.07\$47\$501/ QALY Based on EMPHASIS-HF trial
 Hydralazine-nitrates Hydralazine-nitrates (\$720)Angus (2005)³⁹Y\$19710.26; NA\$10,900\$44,400/ LY Based on A-HeFT trial; assumed treatment efficacy for only a 2-year duration; no QALY data
 Sacubitril-valsartan Sacubitril-valsartan (\$5315)Sandhu (2016)³¹N\$45630.69; 0.62\$29,204\$47,053/ QALY Based on PARADIGM-HF trial
 King (2016)⁴³N\$45601.08; 0.76\$38,633\$50,959/ QALY Based on PARADIGM-HF trial
 Gaziano (2016)³⁶Y\$45001.43; 0.78\$35,200\$45,017/ QALY Based on PARADIGM-HF trial
 Gaziano (2020)⁴⁴Y\$56281.51; 1.24\$27,353\$21,532/QALY Based on PARADIGM-HF and PIONEER-HF; cost-saving when including societal indirect costs
 Ivabradine Ivabradine (\$4706)Kansal (2016)³³Y\$45000.16; 0.20\$4913\$24,920/ QALY Based on SHIFT trial; results displayed for Medicare Advantage population; only a 10-year time horizon
 SGLT-2 inhibitors Dapagliflozin (\$5488)Parizo (2021)⁴⁵Y\$4740.78; 0.46\$38,212\$83,650 QALY Based on DAPA-HF trial;

A-HeFT, African-American Heart Failure; CIBIS-II, Cardiac Insufficiency Bisoprolol Study II; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHEBUS, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; ICER, incremental cost-effectiveness ratio; MDC, Metoprolol in Dilated Cardiomyopathy; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; NA, not available; PARADIGM-HF, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure; PIONEER-HF, Comparison of Sacubitril–Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode; QALY, quality-adjusted life year; SHIFT, Systolic Heart failure treatment with the If inhibitor Ivabradine Trial; SOLVD, Studies of Left Ventricular Dysfunction; V-HeFT II, Vasodilator-Heart Failure Trial II.

*Limited to economic evaluations that include an assessment of clinical benefit via either life-years or quality-adjusted life years and total health care costs. Excluded studies without a medium to long-term time horizon.

[†]Estimated cost based on Medicare Part D spending for the drug. Generic costs were used when available. For nonspecific drugs, the drug with the lowest cost was used. This amount does not include proprietary rebates between patented drugs and pharmaceutical plans, which average over 20% of cost across patented drugs. For individual patients, out-of-pocket costs will vary depending on their pharmaceutical plan.

[‡]When available, cost per quality-adjusted life-years is preferable. For multiple studies, quality-adjusted life-years was not calculated. For these studies, results were represented as \$/life-year gained.

[§]Estimated cost for the lowest cost generic in that class.

^{||}Approximated based on trial drug costs and trial follow-up duration.

[¶]Indicates preferable strategy given lower cost and better clinical outcomes.

**Modeled post-trial outcomes using 3 different patient cohorts leading to range of results.

maximize population health outcomes for diseases such as heart failure.

Devices

Device use in heart failure has increased markedly in the last 40 years. Most devices are tested and approved in patients with heart failure with a reduced ejection fraction, but implantable hemodynamic monitoring devices are approved for use in heart failure with a preserved ejection fraction as well. The economics of devices are less favorable than those for drug therapy. However, because heart failure is, in general, a highly morbid disease with high mortality and expense, it is possible to show that expensive devices can, in certain circumstances, be economically favorable. Cost of technology implementation is highly dependent on geography and most analyses of device cost effectiveness come from the US or European perspective. Devices frequently have less robust randomized trial data before approval than are available for drug therapy, making uncertainty in cost-effectiveness model inputs higher. Finally, as time passes and/or competition develops in a device market, technology costs may decrease. All of these factors increase the uncertainty in cost-effectiveness analyses of heart failure device therapy.

As in all economic assessments, a few factors tend to dominate economic analyses of heart failure devices. These factors include the cost of the device, the risk of death, the risk of hospitalization, and the magnitude of the device's effect to decrease death, hospitalization, or both. Devices with lower reliability, with significant rates of complication or lower durability, are generally associated with increased costs, and this factor will impact economics unfavorably. Some devices may be most effective when applied to a very ill population owing to the magnitude of risk and risk reduction, whereas others may be most effective applied to a less ill population owing to a less dramatic effect that becomes economically more favorable over a longer duration of life.

Defibrillators

Nearly all defibrillator studies show a reduction in sudden cardiac death in the implanted arm.^{60,61} The overall population benefit of the decrease, however, can be highly variable from study to study depending on the background population risk. As a rule, sudden cardiac death risk is highest in ischemic cardiomyopathy, and these studies tend to show clear benefit of defibrillator therapy. A paradoxical issue with implantable cardioverter defibrillators (ICD) studies, particularly primary prevention studies, is that of competing risk. In

lower risk cardiomyopathy populations with a reduced ejection fraction, ICD implantation leads to a decrease in mortality. However, as patient risk increases, competing risk of heart failure death may overwhelm device-related decreases in sudden cardiac death risk and decrease the value of device implantation.

Primary Prevention Defibrillators

The economic case for primary prevention ICDs is more nuanced. If one assumes a benefit of ICD therapy to prolong good quality life, the longer time horizon in primary prevention analyses (3.5 years to lifetime) tends to make these analyses more favorable. The Multicenter Automatic Defibrillator Implantation Trial (MADIT) in ischemic heart failure showed clear efficacy of ICD implantation, leading to highly cost-effective incremental cost-effectiveness ratios based on these criteria from \$19,148 to \$54,802 per quality-adjusted life-year.^{62–65} The case in nonischemic cardiomyopathy depends on the level of risk reduction assumed, and here variability in the randomized trial data makes modeling challenging. Using data from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), models provide an incremental cost-effectiveness ratio in 2011 US dollars between \$79,579 and \$155,400 per quality-adjusted life-year.^{62–64}

Secondary Prevention Defibrillators

Initial trials of ICD implantation in patients who had had an episode of ventricular arrhythmia or sudden cardiac death showed a profound benefit of the devices to reduce mortality when compared with active antiarrhythmic therapy.⁶⁰ The implantation of an ICD for secondary prevention is a Class I, Level of Evidence B recommendation in survivors of sudden death owing to ventricular fibrillation or hemodynamically unstable sustained ventricular tachycardia.⁶¹ Nevertheless, economic models of ICD therapy show a broad range of results, even in the relatively clear-cut case of secondary prevention. A meta-analysis of the economics of ICDs included 7 studies of cost effectiveness for secondary prevention ICDs.⁶² Cost effectiveness was maximized by implanting ICDs in patients with higher risk features or lower ejection fractions. In these cases, incremental cost-effectiveness ratios ranged from \$47,571 per quality-adjusted life-year to \$142,556 per quality-adjusted life-year in 2011 US dollars.

Resynchronization Therapy

Cardiac resynchronization therapy (CRT) has been shown to decrease the risk of death in patients with reduced ejection fraction and prolonged QRS

duration. CRT devices cost approximately one-third that of defibrillators, but because they are implanted in patients with low ejection fractions, they are often combined with defibrillators, increasing the cost of the therapy substantially. The economics of CRT when combined with defibrillator therapy is the subject of a recent systematic review.⁶⁶ This review concluded that CRT vs no therapy was highly cost-effective. The value of CRT with a defibrillator vs ICD alone was not as high, but potentially favorable depending on a society's willingness to pay to improve outcomes.

Using data from the Cardiac Resynchronization in Heart Failure (CARE-HF) trial, the cost-effectiveness of CRT was €19,319 per quality-adjusted life-year (US \$20,000–25,000).⁶⁷ CRT has also been studied in less ill patients in the REVERSE, MADIT-CRT, and RAFT trials.^{68–70} A meta-analysis examining the cost effectiveness of CRT in mild heart failure estimated a cost-effectiveness ratio of \$61,700 per quality-adjusted life-year gained.⁷¹ Recent reports examining the long-term efficacy of CRT in mild heart failure have led to more favorable estimates of cost for CRT therapy, even in mild heart failure, with borderline cost effectiveness when combined with defibrillator therapy if one assumes a sustained decrease in mortality.

Implanted Circulatory Support Devices

Data regarding the cost effectiveness of durable mechanical circulatory support (MCS) devices have recently been summarized in a systematic review.⁷² Implanted MCS devices increase life expectancy and quality of life in patients with advanced heart failure,^{73–77} but are associated with obligatory upfront technology costs, as well as substantial outpatient and readmission costs. A few studies have shown incremental cost-effectiveness ratios for use of MCS as a bridge to transplant near US\$80,000 per quality-adjusted life-year (2017 dollars),^{78–82} but others show incremental cost-effectiveness ratios for this strategy in excess of \$100,000⁸² or even \$200,000 per quality-adjusted life-year gained.⁸³ One study suggested incremental cost-effectiveness ratios for long-term, or destination, MCS strategy near \$200,000 per quality-adjusted life-year.⁸³ One analysis, however, did show a profound decrease in post-discharge costs with the newest HeartMate 3 device compared with costs for the HeartWare device (no longer manufactured), driven by a decrease in rehospitalizations, suspected pump thrombosis, and stroke.⁷⁷ An ongoing assessment of costs as these technologies evolve is essential.^{84,85} Cost-effectiveness analyses are not currently available for short-term devices used as acute therapy in critically ill patients with cardiogenic shock, which is partially

related to limited data regarding the relative efficacy of different treatment strategies in this scenario.

Cardiac Transplantation

Long et al⁸⁶ compared heart transplant with destination therapy left ventricular assist device and medical therapy among transplant-eligible patients with inotrope-dependent stage D heart failure. They used data from International Society for Heart and Lung Transplantation registry and the REMATCH trial and performed 2 analyses—a 5.6-month and 12.0-month waitlist for transplantation. They estimated that transplantation led to improved outcomes and lower cost than destination therapy with a left ventricular assist device in both scenarios. Compared with medical therapy, they estimated transplant led to 4.12 additional quality-adjusted life-years at a lifetime incremental cost of \$398,700 with a 5.6-month waitlist. This led to a cost per quality-adjusted life-year of \$96,900 of transplant relative to medical therapy with similar results with the 12.0-month waitlist. The primary caveats are the basing of effectiveness estimates on observational data and the advances in transplant outcomes over time.

Mitral Valve Transcatheter Edge to Edge Repair

An analysis using the COAPT study results⁸⁷ found that transcatheter mitral valve transcatheter edge-to-edge repair (TEER) using the Mitraclip device (procedural cost \$35,755) among patients with severe secondary mitral regurgitation would improve survival by 1.13 years (0.83 quality-adjusted life-years) and increase cost by \$45,648 compared with medical therapy alone for a cost-effectiveness ratio of \$55,600 per quality-adjusted life-year.⁸⁸ The benefit noted in the COAPT study has led to a 2A recommendation for TEER in the American College of Cardiology/American Heart Association clinical guidelines.⁸⁹ However, a second randomized controlled trial (MITRA-FR) using a similar population found the rate of death or unplanned hospitalization for heart failure at 1 year did not differ significantly between patients who underwent TEER and those who received medical therapy alone.⁹⁰ The uncertainty in the benefit makes it difficult to draw conclusions regarding the value of mitral valve TEER.

Diagnostic and Monitoring Tests

Although clinical examination and assessment remain the gold standard for screening and diagnosing heart failure, new technological developments have added several options for clinicians managing patients with heart failure.

Brain natriuretic peptide (BNP) and N-terminal (NT) pro-BNP are now routinely used in clinical practice for the diagnosis of heart failure. The use of BNP to diagnose heart failure in patients with dyspnea has been shown to be cost effective.⁹¹ More recently, there has been growing interest in using NT pro-BNP–guided management of chronic heart failure, and a 2016 Cochrane review found reduction in heart failure admissions (38% vs 28%, relative risk 0.70, 95% confidence interval 0.61–0.80, $n=1928$ patients, 10 studies, low quality of evidence) though no difference was found in any other clinical outcome.⁹² Three of 4 studies that assessed cost found it to be cost saving. A more recent randomized controlled trial funded by the National Institutes of Health, GUIDE-IT, which was published after this Cochrane review, however, did not show any difference in any of the clinical or quality-of-life outcomes, including heart failure hospitalizations.⁹³ Costs also averaged \$5919 higher in the NT pro-BNP guided arm (95% confidence interval $-\$1,795$ to $+\$13,602$). Given the conflicting data, the cost effectiveness of using natriuretic peptides for management of patients with heart failure remains uncertain.

Community screening with BNP followed by echocardiography was explored in an economic analysis.⁹⁴ Performance of BNP in asymptomatic men and women more than 60 years of age, followed by echocardiography, resulted in increased lifetime cost of care (\$176,000 US for screening 1000 men, \$101,000 dollars for screening 1000 women) and improved outcome (7.9 quality-adjusted life years for 1000 men and 1.3 quality-adjusted life-years for 1000 women), resulting in a cost per quality-adjusted life-year of \$22,300 US for men and \$77,700 US for women.⁹³

There has also been considerable interest in using invasive hemodynamic measures to manage chronic heart failure. CardioMEMS (CardioMEMS Heart Failure System, St Jude Medical Inc, Atlanta, GA) is one such device that has been approved by the Food and Drug Administration.⁹⁵ However, cost effectiveness studies show mixed results ranging from high to intermediate value.^{86–98} Sandhu et al found a cost of \$71,462 per quality-adjusted life-year gained.⁸⁸ The most important determinants of the device's cost effectiveness were the durability of its effect on hospitalization and mortality over time. A recent trial found less efficacy of CardioMEMS though the population differed.⁹⁹ Thus, the cost effectiveness of CardioMEMS is unclear and requires further study.

Cost and Value in Heart Failure Guidance Documents

As noted elsewhere in this article, the American College of Cardiology/American Heart Association have published recommendations for including

statements on cost-effectiveness and value in clinical practice guidelines and performance measure documents.²⁴ A recent review of 33 clinical guidance documents for heart failure found that 27 (82%) included at least 1 cost or value statement, although most of these focused on the high economic impact of heart failure.¹⁰⁰ Three documents (9%) reported estimated costs of interventions and 1 estimated out-of-pocket costs.

Summary

The cost of heart failure care is growing owing to the aging of the population and the development and new effective but costly therapies. This review has summarized the value of different care strategies and a graphical representation of these is shown in Fig. 2. The review focused on high-profile heart failure management strategies and published cost-effectiveness data. Thus, other important heart failure care interventions such as rehabilitation and palliative care were not included.

Given limited health care budgets, policymakers must consider the economic value that each treatment or test provides. Policies are needed to minimize out of pocket costs for all high value heart failure treatments. Such policies will directly lead to lives saved and healthier days out of hospital for patients with heart failure.

Disclosures

PAH: None. GCF: Consulting for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis. YO: None. ATS receives research support from the National Heart, Lung, and Blood Institute (1K23HL151672-01). ATS consults for Acumen, LLC. HJW: Advisor for Embrace Prevention Care. NKS: None.

Declaration of competing interest

None.

References

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. *Circulation* 2020;141:e139–596.
2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council.

- Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013;6:606–19.
3. Tran DT, Ohinmaa A, Thanh NX, Howlett JG, Ezekowitz JA, McAlister FA, et al. The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. *CMAJ Open* 2016;4:E365–70.
 4. Khan SU, Khan MZ, Alkhouli M. Trends of clinical outcomes and health care resource use in heart failure in the United States. *J Am Heart Assoc* 2020;9:e016782.
 5. Yoon J, Fonarow GC, Groeneveld PW, Teerlink JR, Whooley MA, Sahay A, et al. Patient and facility variation in costs of VA heart failure patients. *JACC Heart Fail* 2016;4:551–8.
 6. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. *BMC Cardiovasc Disord* 2018;18:74.
 7. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. *J Am Coll Cardiol* 2017;70:2476–86.
 8. Ody C, Msall L, Dafny LS, Grabowski DC, Cutler DM. Decreases in readmissions credited to Medicare's program to reduce hospital readmissions have been overstated. *Health Aff (Millwood)* 2019;38:6–43.
 9. Psotka MA, Fonarow GC, Allen LA, Joynt Maddox KE, Fiuzat M, Heidenreich P, et al. The Hospital Readmissions Reduction Program: nationwide perspectives and recommendations: A JACC: Heart Failure Position Paper. *JACC Heart Fail* 2020;8:1–11.
 10. Gupta A, Allen LA, Bhatt DL, Cox M, DeVore AD, Heidenreich PA, et al. Association of the Hospital Readmissions Reduction Program implementation with readmission and mortality outcomes in heart failure. *JAMA Cardiol* 2018;3:44–53.
 11. Wadhera RK, Joynt Maddox KE, Wasfy JH, Haneuse S, Shen C, Yeh RW. Association of the Hospital Readmissions Reduction Program with mortality among Medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and pneumonia. *JAMA* 2018;320:2542–52.
 12. Khera R, Wang Y, Nasir K, Lin Z, Krumholz HM. Evaluation of 30-day hospital readmission and mortality rates using regression-discontinuity framework. *J Am Coll Cardiol* 2019;74:219–34.
 13. Blum MR, Øien H, Carmichael HL, Heidenreich P, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of transitional care services after hospitalization with heart failure. *Ann Intern Med* 2020;172:248–57. <https://doi.org/10.7326/M19-1980>.
 14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128:1810–52.
 15. Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, et al. Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the PACT-HF randomized clinical trial. *JAMA* 2019;321:753–61.
 16. Chang PP, Wruck LM, Shahar E, Rossi JS, Loehr LR, Russell SD, et al. Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005–2014): ARIC Study Community Surveillance. *Circulation* 2018;138:12–24.
 17. Severino P, D'Amato A, Saglietto A, D'Ascenzo F, Marini C, Schiavone M, et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. *ESC Heart Fail* 2020;7:4182–8.
 18. Toner L, Koshy AN, Ko J, Driscoll A, Farouque O. Clinical characteristics and trends in heart failure hospitalizations: an Australian experience during the COVID-19 lockdown. *JACC Heart Fail* 2020;8:872–5.
 19. Frankfurter C, Buchan TA, Kobulnik J, Lee DS, Luk A, McDonald M, et al. Reduced rate of hospital presentations for heart failure during the COVID-19 pandemic in Toronto, Canada. *Can J Cardiol* 2020;36:1680–4.
 20. Hall ME, Vaduganathan M, Khan MS, et al. Reductions in heart failure hospitalizations during the COVID-19 pandemic. *J Card Fail* 2020;26:462–3.
 21. Bhatt AS, Moscone A, McElrath EE, et al. Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic. *J Am Coll Cardiol* 2020;76:280–8.
 22. Gorodeski EZ, Goyal P, Cox ZL, Thibodeau JT, Reay RE, Rasmusson K, et al. Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. *J Card Fail* 2020;26:448–56.
 23. Charman SJ, Velicki L, Okwose NC, Harwood A, McGregor G, Ristic A, et al. Insights into heart failure hospitalizations, management, and services during and beyond COVID-19. *ESC Heart Fail* 2020;8:175–82.
 24. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, ACC/AHA Task Force on Performance Measures; ACC/AHA Task Force on Practice Guidelines. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. *Circulation* 2014;129:2329–45.
 25. The World Bank. GDP per capita, United States. Available at: <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2019&locations=US&start=2019&view=chart>. Accessed December 13, 2020.
 26. Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. *Ann Intern Med* 2020;174:25–32.
 27. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599–726.
 28. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. *Circulation* 2005;111:1106–13.
 29. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. *J Am Coll Cardiol* 1995;26:914–9.
 30. Shekelle P, Morton S, Atkinson S, et al. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. *Evid Rep Technol Assess (Summ)* 2003:1–6.

31. Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. *Ann Intern Med* 2016; 165:681–9.
32. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. *Arch Intern Med* 1994;154:1143–9.
33. Kansal AR, Cowie MR, Kielhorn A, et al. Cost-effectiveness of ivabradine for heart failure in the United States. *J Am Heart Assoc* 2016;5:e003221.
34. Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. *Am J Med* 2001;110:745–80S. Suppl 7A).
35. Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic evaluation of the Randomized Aldactone Evaluation Study (RALES): treatment of patients with severe heart failure. *Cardiovasc Drugs Ther* 2002;16:53–9.
36. Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. *JAMA Cardiol* 2016;1:666–72.
37. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. *Am J Cardiol* 1999;83:890–6.
38. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. *J Am Coll Cardiol* 2013;61:1440.. –32.
39. Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. *Circulation* 2005;112:3745–53.
40. McEwan P, Darlington O, McMurray JJV, Jhund PS, Docherty KF, Böhm M, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. *Eur J Heart Fail* 2020;22:2147–56. <https://doi.org/10.1002/ejhf.1978>. Epub 2020 Sep 15. PMID: 32749733.
41. Isaza N, Calvachi P, Shen C, Gavin MC, Garan AR, Bellows BK, et al. Cost-effectiveness of dapagliflozin in heart failure with reduced ejection fraction. *Circulation* 2020;142:A15981. (abstract).
42. Echouffo-Tcheugui JB, Bishu KG, Fonarow GC, Egede LE. Trends in health care expenditure among US adults with heart failure: The Medical Expenditure Panel Survey 2002–2011. *Am Heart J* 2017;186:63–72.
43. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. *JACC Heart Fail* 2016;;4:392–402.
44. Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. *JAMA Cardiol* 2020;5:1236–44.
45. Parizo JT, Goldhaber-Fiebert JD, Salomon JA, Khush KK, Spertus JA, Heidenreich PA, et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. *JAMA Cardiol* 2021;6:926–35.
46. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med* 2018;379:1007–16.
47. Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. *Circulation* 2020;141:1214–24.
48. Bounthavong M, Butler J, Dolan CM, et al. Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia. *Pharmacoeconomics* 2018;36:1463–73.
49. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med* 2015;372:211–21.
50. Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS™ HF System (St. Jude Medical, Inc.) and sacubitril/valsartan (Entresto™, Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. Institute for Clinical and Economics Review; December 1 2015 Available at: https://icer-review.org/wp-content/uploads/2016/01/CHF_Final_Report_120115.pdf.
51. Ollendorf DA, Sandhu AT, Pearson SD. Sacubitril-valsartan for the treatment of heart failure: effectiveness and value. *JAMA Intern Med* 2016;176:249–50.
52. Bergethon KE, Wasfy JH. Increasing the adoption and diffusion of a novel pharmacological therapy that is both mortality reducing and cost-effective. *J Am Heart Assoc* 2019;8:e011783.
53. Resneck JS. Refocusing medication prior authorization on its intended purpose. *JAMA* 2020;323:703–4.
54. Gourzoulidis G, Kourlaba G, Stafylas P, Giamouzis G, Parisis J, Maniadakis N. Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. *Health Policy* 2017;121:363–77.
55. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. *JAMA* 2007;298:61–9.
56. Wang TY, Kaltenbach LA, Cannon CP, et al. Effect of Medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial. *JAMA* 2019;321:44–55.
57. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. *N Engl J Med* 2011;365:2088–97.
58. Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM. Adoption of sacubitril/valsartan for the management of patients with heart failure. *Circ Heart Fail* 2018;11:e004302.
59. Sandhu AT, Heidenreich PA. The affordability of guideline-directed medical therapy: cost sharing is a critical barrier to therapy adoption. *Circulation* 2021;143:1073–5.
60. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J* 2000;21:2071–8.
61. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* 2018;15:e190–252.
62. Garcia-Perez L, Pinilla-Dominguez P, Garcia-Quintana A, Caballero-Dorta E, Garcia-Garcia FJ, Linertova

- R, et al. Economic evaluations of implantable cardioverter defibrillators: a systematic review. *Eur J Health Econ* 2015;16:879–93.
63. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. *N Engl J Med* 2005;353:1471–80.
 64. Alcaraz A, González-Zuelgaray J, Augustovski F. [Cost effectiveness of implantable cardioverter-defibrillators for patients who are at risk for sudden death in Argentina]. *Value Health* 2011;14:S33–8.
 65. Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Cost-effectiveness of implantable cardioverter defibrillators in patients ≥ 65 years of age. *Am Heart J* 2010;160:122–31.
 66. Tomini F, Prinzen F, van Asselt AD. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure. *Eur J Health Econ* 2016;17:1159–72.
 67. Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. *Eur Heart J* 2005;26:2681–8.
 68. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol* 2008;52:1834–43.
 69. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med* 2009;361:1329–38.
 70. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* 2010;363:2385–95.
 71. Woo CY, Strandberg EJ, Schmiegelow MD, Pitt AL, Hlatky MA, Owens DK, et al. Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. *Ann Intern Med* 2015;163:417–26.
 72. Schmier JK, Patel JD, Leonhard MJ, Midha PA. A systematic review of cost-effectiveness analyses of left ventricular assist devices: issues and challenges. *Appl Health Econ Health Policy* 2019;17:35–46.
 73. Rose EA, Gelijs AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 2001;345:1435–43.
 74. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Sixth INTERMACS annual report: a 10,000-patient database. *J Heart Lung Transplant* 2014;33:555–64.
 75. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 2009;361:2241–51.
 76. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. *J Am Coll Cardiol* 2009;54:312–21.
 77. Mehra MR, Uriel N, Naka Y, Cleveland JC, Yuzefpolskaya M, Salerno CT, et al. a fully magnetically levitated left ventricular assist device - final report. *N Engl J Med* 2019;380:1618–27.
 78. Clarke A, Pulikottil-Jacob R, Connock M, Suri G, Kandala NB, Maheswaran H, et al. Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program. *Int J Cardiol* 2014;171:338–45.
 79. Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, et al. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. *Health Technol Assess* 2013;17:1–499. v-vi.
 80. Sharples LD, Dyer M, Cafferty F, Demiris N, Freeman C, Banner NR, et al. Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK). *J Heart Lung Transplant* 2006;25:1336–43.
 81. Moreno SG, Novielli N, Cooper NJ. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. *J Heart Lung Transplant* 2012;31:450–8.
 82. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. *Circ Heart Fail* 2014;7:470–8.
 83. Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure. *JACC Heart Fail* 2017;5:110–9.
 84. Mahr C, McGee E Jr, Cheung A, Mokadam NA, Strueber M, Slaughter MS, et al. Cost-effectiveness of thoracotomy approach for the implantation of a centrifugal left ventricular assist device. *ASAIO J* 2020;66:855–61.
 85. Silvestry SC, Mahr C, Slaughter MS, Levy WC, Cheng RK, May DM, et al. Cost-effectiveness of a small intrapericardial centrifugal left ventricular assist device. *ASAIO J* 2020;66:862–70.
 86. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. *Circ Heart Fail* 2014;7:470–8.
 87. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018;379:2307–18.
 88. Baron SJ, Wang K, Arnold SV, Magnuson EA, Whisenant B, Brieke A, COAPT Investigators. Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT Trial. *Circulation* 2019;140:1881–91.
 89. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2021;77:450–500.
 90. Obadia JF, Messika-Zeitoun D, Leurent G, Lung B, Bonnet G, Piriou N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med* 2018;379:2297–306.
 91. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. *Arch Intern Med* 2006;166:1081–7.

92. McLellan J, Heneghan CJ, Perera R, et al. B-type natriuretic peptide-guided treatment for heart failure. *Cochrane Database Syst Rev* 2016;12. CD008966.
93. Mark DB, Cowper PA, Anstrom KJ, et al. Economic and quality-of-life outcomes of natriuretic peptide-guided therapy for heart failure. *J Am Coll Cardiol* 2018;72:2551–62.
94. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. *J Am Coll Cardiol* 2004;43:1019–26.
95. Givertz MM, Stevenson LW, Costanzo MR, et al. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. *J Am Coll Cardiol* 2017;70:1875–86.
96. Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA. Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. *JACC Heart Fail* 2016;4:368–75.
97. Schmier JK, Ong KL, Fonarow GC. Cost-effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system. *Clin Cardiol* 2017;40:430–6.
98. Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB. Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. *Eur J Heart Fail* 2017;19:652–60.
99. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): randomised controlled trial. *Lancet* 2021;398:991–1001.
100. Ostrominski JW, Hirji S, Bhatt AS, Butler J, Fiuzat M, Fonarow GC, et al. Cost and value in contemporary heart failure clinical guidance documents. *J Am Coll Cardiol* 2022;10:1–11.